Editorial

» opinion, clinical trials and immunology

Most Recent

image: Stubbornly Persistent

Stubbornly Persistent

By | February 1, 2015

Microorganisms continually challenge our assumptions of what life can achieve.

1 Comment

image: Making Cancer More Transparent

Making Cancer More Transparent

By | April 1, 2013

A decade into the age of genomics, science is generating a flood of data that will help in the quest to eradicate the disease.

3 Comments

image: A Chill Issue

A Chill Issue

By | February 1, 2013

The very cold, the merely chilled, and the colorful

0 Comments

image: In the Long Run

In the Long Run

By | December 1, 2012

Can emulating our early human ancestors make us healthier?

1 Comment

image: Avant-Garde Science

Avant-Garde Science

By | June 1, 2012

Why naked mole-rats and experimental gene therapies remind me of groundbreaking artists.

0 Comments

image: With All Due Consideration

With All Due Consideration

By | May 1, 2012

Scientists and their many hats

2 Comments

image: Tricky Trials

Tricky Trials

By | March 1, 2012

Studies on safety, efficacy, or dosing of drugs in children, or on nutritional supplements, are not run-of-the-mill.

0 Comments

A Truly Happy Return

By | December 1, 2011

After a roller-coaster of an October, The Scientist resumes publication under new ownership.

12 Comments

image: A Shot in the Arm

A Shot in the Arm

By | June 1, 2011

Decades of vaccine research have expanded our understanding of the immune system and are yielding novel disease-fighting tactics.

0 Comments

image: To Err is Human

To Err is Human

By | February 1, 2011

This is your brain on emotions.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech